Study of Optimal Treatment Plan in Hypertensives With Anti-AT1-Receptor Autoantibody
Phase 4
- Conditions
- Hypertension
- Registration Number
- NCT00360763
- Lead Sponsor
- Huazhong University of Science and Technology
- Brief Summary
The autoantibodies against AT1 receptor (ATR-AA), behaving like an agonist were detected in patients with hypertension. ATR-AA which can blocked by ARB may play a role in the pathogenesis of hypertension. The present study is to explore whether AT1 receptor blocker has superior anti-hypertensive effect in patients with positive ATR-AA hypertension. Patients with 2 grade hypertension were recruited and ATR-AA was assayed by ELISA. A study was carried out and the efficacy of anti-hypertension was compared between candesartan cilexetil and ACE inhibitor imidapril.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 600
Inclusion Criteria
- Hypertension (2 grade)
Exclusion Criteria
- Secondary hypertension
- Known sensitivity or intolerance to an angiotensin II receptor antagonist or ACE inhibitor
- Pregnancy
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Department of Cardiology, Wuhan Union Hospital
🇨🇳Wuhan, Hubei, China